Development of novel treatment strategies based on knowledge of cellular dysfunction in diabetes (BetaBat)
Research Areas
At a Glance
- Status: Active Consortium
- Year Launched: 2011
- Initiating Organization: European Commission Seventh Framework Programme (FP7)
- Initiator Type: Government
- Disease focus:
Diabetes - Location: Europe
Abstract
The European project BetaBat aims to develop new treatment strategies based on knowledge of cellular dysfunction in diabetes.
Mission
BetaBat will perform a detailed organelle diagnosis based on both focused and systems biology approaches, which will provide the scientific rationale for the design of specific interventions to boost the capacity of beta cells and brown adipocytes to regain homeostatic control. The project proposes that only by understanding the complex molecular mechanisms triggering cellular dysfunction in diabetes, and by integrating this knowledge at the systems level, will it be possible to develop interventional therapies that protect and restore beta cell and BAT function. The ultimate goal is to offer individual therapeutic choices based on both genetic information and organelle diagnosis.
Consortium History
The project was launched in October 2011.
Financing
BetaBat is a collaborative project funded by the European Commission under the Seventh Framework Programme.
Links/Social Media Feed
|
Homepage |
Points of Contact
Prof. Décio L. Eizirik (coordinator)
U.L.B. CP618
Route de Lennik 808
1070 Brussels (Anderlecht)
Belgium
phone: ++32 (0)2 555 6242
email: deizirik@ulb.ac.be
Sponsors & Partners
|
DNA Vision SA |
|
Lund University |
|
Medizinische Hochschule Hannover |
|
Sanford-Burnham Medical Research Institute |
|
Sirion Biotech |
|
Universitat de Barcelone |
|
Universite de Lausanne |
|
Universite Libre de Bruxelles |
|
University of Cambridge |
|
VTT Technical Research Centre of Finland |